NEKTAR THERAPEUTICS annual report, Q4 FY2010

Business Context and Reporting Period

Company: Nektar Therapeutics
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Nektar is a clinical-stage biopharmaceutical company developing drug candidates using proprietary PEGylation and advanced polymer conjugate technology platforms. The company focuses on oncology, pain, anti-infectives, and immunology. Key proprietary candidates include NKTR-118 (partnered with AstraZeneca for opioid-induced constipation) and NKTR-102 (a topoisomerase I inhibitor for various cancers). The company also generates revenue through licensing and manufacturing agreements with partners such as Amgen, Roche, and Bayer.

Key Financial Metrics

Metric (in thousands) 2010 2009
Total Revenue $159,039 $71,931
Net Loss $(37,938) $(102,519)
Loss Per Share (Basic & Diluted) $(0.40) $(1.11)
Research & Development Expense $108,065 $95,109
Cash, Cash Equivalents & Investments $315,932 $396,211
Convertible Subordinated Notes (Debt) $214,955 $214,955
Working Capital $289,871 $260,650

Liquidity: As of December 31, 2010, the company held approximately $315.9 million in cash and short-term investments. Total indebtedness was approximately $240.4 million, primarily consisting of $215.0 million in convertible notes due September 2012.

Material Changes vs. Prior Period

  • Revenue Surge: Total revenue increased 121% to $159.0 million in 2010 compared to $71.9 million in 2009. This was primarily driven by the recognition of $101.4 million of the $125.0 million upfront payment received from AstraZeneca in late 2009 for the NKTR-118 and NKTR-119 license agreement. AstraZeneca represented 68% of total revenue in 2010.
  • Improved Net Loss: Net loss narrowed significantly to $37.9 million in 2010 from $102.5 million in 2009, largely due to the revenue recognition mentioned above.
  • Impairment Charge: The company recorded a $12.6 million impairment charge in 2010 related to the relocation of its corporate headquarters and R&D operations from San Carlos to a new facility in Mission Bay, San Francisco. This charge was not present in 2009.
  • R&D Expenses: R&D expenses increased 14% to $108.1 million, driven by increased headcount, stock-based compensation, and facility costs, partially offset by lower outside service costs for partnered programs.

Guidance, Outlook, and Risks

Outlook and Strategy:

  • NKTR-102 Development: Management announced plans to advance NKTR-102 into Phase 3 clinical development for metastatic breast cancer and platinum-resistant/refractory ovarian cancer without a collaboration partner, bearing the majority of development costs. Phase 3 trials are expected to begin in late 2011.
  • Revenue Expectations: Management expects license, collaboration, and other revenue to substantially decrease in 2011 as the upfront payment from AstraZeneca has been fully recognized.
  • Capital Needs: The company stated it does not have sufficient resources to fund its R&D pipeline, complete late-stage development of NKTR-102, and repay its $215 million convertible notes due in September 2012. It plans to explore restructuring the notes or raising additional capital.

Subsequent Event: On January 24, 2011, the company completed a public offering of common stock, raising approximately $220.4 million in net proceeds.

Key Risks:

  • Liquidity and Debt: Significant risk of inability to repay $215 million in convertible notes due in 2012 without restructuring or additional financing.
  • Clinical Trial Failure: High risk of failure in clinical trials for proprietary candidates (NKTR-102, NKTR-181) and partnered programs (Amikacin Inhale).
  • Customer Concentration: Heavy reliance on AstraZeneca, which accounted for 68% of 2010 revenue.
  • Manufacturing: Delays in finalizing device design for Amikacin Inhale have pushed back Phase 3 trials.

Investor Verification Checklist

  • Debt Maturity: Verify the status of the $215 million convertible notes due September 2012 and any progress on restructuring or refinancing.
  • NKTR-102 Phase 3 Costs: Confirm the estimated budget and timeline for the self-funded Phase 3 trials of NKTR-102, as this will be a major cash drain.
  • Revenue Sustainability: Assess the pipeline of future milestone payments and royalties to replace the one-time AstraZeneca revenue recognized in 2010.
  • Amikacin Inhale Status: Monitor updates on the device design finalization and the start date of Phase 3 trials with Bayer.
  • Stock Offering Impact: Review the dilution impact of the January 2011 stock offering and the specific use of the $220.4 million raised.